Simple Summary This review aims to analyze the emerging issue regarding PARP inhibitor's
resistance in tumors and their consequence on disease prognosis and treatment. Besides …

Due to the DNA repair defect, BRCA1/2 deficient tumor cells are more sensitive to PARP
inhibitors (PARPi) through the mechanism of synthetic lethality. At present, several PAPRi …

Simple Summary PARP inhibitors (PARPi) are current treatment options for patients with
ovarian, breast, pancreatic or prostate cancer. Although PARPi have transformed the patient …

Poly-(ADP-ribose) polymerase (PARP) inhibitors act through synthetic lethality in cells with
defects in homologous recombination (HR) DNA repair caused by molecular aberrations …

Breast cancer and gynecological tumors seriously endanger women's physical and mental
health, fertility, and quality of life. Due to standardized surgical treatment, chemotherapy, and …

Developing novel targeted anticancer therapies is a major goal of current research. The use
of poly (ADP-ribose) polymerase (PARP) inhibitors in patients with homologous …

Given the malleable nature of cancer cells, we should expect, and do see, the development
of resistance to any new chemotherapeutic agent. Models that help us understand how this …

Poly (ADP-ribose) polymerase inhibitors (PARPi) are a new class of agents with
unparalleled clinical achievement for driving synthetic lethality in BRCA-deficient cancers …

PARP inhibitors (PARPi) are a kind of cancer therapy that targets poly (ADP-ribose)
polymerase. PARPi is the first clinically approved drug to exert synthetic lethality by …

The abundant nuclear enzyme poly (ADP-ribose) polymerase-1 (PARP-1) represents an
important novel target in cancer therapy. PARP-1 is essential to the repair of single strand …